Zoetis falls on lowered annual outlook
BUZZ-Zoetis falls on lowered annual outlook ** Zoetis ZTS.N shares fall 2.53% to $72.51 in premarket trading
** The animal health company expects 2026 adj. EPS of $6.15-$6.25 per share, compared with its prior forecast $6.85-$7.00 per share
** Expects 2026 revenue of $9.12 billion-$9.32 billion, down from prior view $9.68 billion-$9.96 billion; analysts on average were expecting $9.73 bln, according to data compiled by LSEG
** Posts Q2 adj. EPS of $1.87 vs est. $1.86
** "Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories," said CEO Kristin Peck
** As of last close, stock down ~41% YTD
(Reporting by Sahil Pandey and Sriparna Roy in Bengaluru)
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies